维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

1篇 您的检索式：作者名="Formann E."

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	干扰素α-2a加利巴韦林联用或不用金刚烷胺对慢性丙型肝炎病毒基因1型感染者的治疗:一项随机、双盲、安慰剂对照研究显示文摘Background/Aims: Amantadine may augment virological response rates to interferon-based therapy in chronic hepatitis C patients. Using a novel design, amantadine was studied in na ve genotype 1 patients treated in combination with peginterferon alfa-2a (40KD)/ribavirin. Methods: Patients enrolled in this randomized, placeo-controlled multicenter trial were stratified by single-dose interferon sensitivity (stratum I, 24 h HCV-RNA decline >1.4log 10; II, 0.8-1.39log10; III, < 0.8log10; a reliable means of identifying nonresponders to interferon/ribavirin) and fibrosis grade (F0/1/2 vs. F3/4) at baseline. All patients received peginterferon alfa-2a (40KD) 180 μ g/week plus ribavirin 1000-1200 mg/day and were randomized to receive amantadine 100 mg twice daily (N=114) or placebo (N=95) for 48 weeks. Results: Week 24 virological response rates in strata II and III, the primary outcome, were similar in patients treated with amantadine (63.7% ) or placebo (65.7% ), as were sustained virological response rates at week 72 (46.5 and 51.6% , respectively). Adverse event profiles were similar and amantadine did not improve health-related quality of life compared with placebo. Interferon sensitivity was the only significant predictor of treatment outcome. Conclusions: Adding amantadine to peginterferon alfa-2a (40KD)/ribavirin combination therapy does not augment virological response rates in genotype 1 patients. Virological response was almost exclusively determined by interferon sensitivity at baseline.	Ferenci P. Formann E. Laferl H. 刘丽娜	2006	世界核心医学期刊文摘(胃肠病学分册)2006，2，5：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费